免疫检查点抑制剂在恶性淋巴瘤治疗中的研究进展被引量：1

Advance in the study of immune checkpoint inhibitors in the treatment of malignant lymphoma

下载PDF

导出

摘要恶性淋巴瘤的靶向免疫检查点治疗通过阻断免疫抑制信号的传递,提高T细胞的抗肿瘤免疫反应,激活抗肿瘤的免疫效应,这种治疗方法可以获得持久的临床效应,成为恶性淋巴瘤治疗的新选择。现已发现的免疫检查点主要有程序性细胞死亡蛋白-1(Programmed death-1,PD-1)、细胞毒性T淋巴细胞相关抗原-4(Cytotoxic T lymphocyte associated-4,CTLA-4)和程序性死亡配体-1(Programmed death ligand 1,PD-L1)。本文简要综述了PD-1抑制剂、CTLA-4抑制剂及PD-Ll抑制剂在恶性淋巴瘤治疗中的研究进展,以及免疫的耐药机制和应对方法。 Targeted immune checkpoint therapy in malignant lymphoma, by blocking the transmission of immunosuppressive signals, could improve T cell anti-tumor immune response and activate anti-tumor immune effect. This treatment can achieve lasting clinical effects and has become a new choice of treatment for malignant lymphoma. The immune checkpoints found are mainly PD-1, CTLA-4 and PD-L1. This paper briefly reviews PD-1 inhibitors, CTLA-4 inhib- itors and PD-L1 inhibitors in the treatment of malignant lymphoma and the immune resistance mechanism and coping methods.

作者宋丹高宏宇杨威

机构地区中国医科大学附属盛京医院第二血液内科

出处《实用药物与临床》 CAS 2018年第1期104-108,共5页 Practical Pharmacy and Clinical Remedies

关键词恶性淋巴瘤免疫检查点抑制剂免疫耐药 Malignant lymphoma Immune checkpoint inhibitors Immune resistance

分类号 R733.1 [医药卫生—肿瘤]

引文网络
相关文献

参考文献1

1Mark F van Delft,David CS Huang.How the Bcl-2 family of proteins interact to regulate apoptosis[J].Cell Research,2006,16(2):203-213. 被引量：39

二级参考文献116

1Rinkenberger JL, Homing S, Klocke B, et al, Mcl-1 deficiency results in oeri-implantation embryonic lethality, Genes Dev 2000;14:23-7
2Motoyama N, Wang FP, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science 1995; 267:1506-10.
3Opfen,nan J, Iwasaki H, Ong CC, et al. Obligate role of antiapoptotic Mcl-1 in the survival of hematopoietic stem cells.Science. 2005; 307:1101-4.
4Adams JM. Ways of dying: multiple pathways to apoptosis.Genes Dev 2003; 17:2481-95.
5Danial NN, Korsmeyer SJ. Cell death: critical control points.Cell 2004; 116:205-19.
6Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590-8607.
7Bomer C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39:615-647.
8Hinds MG, Laclonann M, Skea GL, et al. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J 2003; 22:1497-507.
9Denisov AY, Madiraju Ms, Chen G, et al. Solution structure of human Bcl-w: modulation of ligand binding by the C-terminal helix. J Biol Chem 2003; 278:21124-8.
10Day CL, Chen L, Richardson SJ, et al. Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Pro-apoptosis BH3-only Ligands. J Biol Chem 2005; 280:4738-44.